InCarda Therapeutics
Brisbane, US · Founded 2009 · Delaware corporation · 11 employees on LinkedIn · 4 known investors
Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.
Founders & leadership
RN
Rangachari NarasimhanExecutive
GC
Grace ColonExecutive
MS
Miller SamanthaExecutive
CA
Carlos A. SchulerNamed on SEC filing
JS
John S. PattonNamed on SEC filing
Board
MR
McCarthy ReenieBoard director
BN
Bischofberger NorbertBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$66M disclosed across 4 rounds · 2013–2020
▶$28MraisedOct 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$28MraisedOct 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew ElBardissiDirector
- Johan ChristensonDirector
- Alan ColowickDirector
- Isaac ChengDirector
- Grace ColonExecutive Officer, Director
- Dan WelchDirector
- Offering amount
- $50M
- Amount sold
- $28M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35.3MraisedNov 2019 · 24 investors · PharmaceuticalsRule 506(b)
▶$35.3MraisedNov 2019 · 24 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Grace ColonExecutive Officer, Director
- Isaac ChengDirector
- Bischofberger NorbertDirector
- Alan ColowickDirector
- Johan ChristensonDirector
- Andrew ElBardissiDirector
- Dan WelchDirector
- Offering amount
- $42.1M
- Amount sold
- $35.3M
- Minimum investment
- $1.8K
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedMay 2017 · 16 investors · PharmaceuticalsRule 506(b)
▶$2.1MraisedMay 2017 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Rangachari NarasimhanExecutive Officer, Director
- McCarthy ReenieDirector
- Grace ColonExecutive Officer, Director
- Bischofberger NorbertDirector
- Miller SamanthaExecutive Officer
- Offering amount
- $2.5M
- Amount sold
- $2.1M
- Minimum investment
- $5K
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$567KraisedDec 2014 · 13 investors · PharmaceuticalsRule 506(b)
▶$567KraisedDec 2014 · 13 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Grace ColonExecutive Officer, Director
- Carlos A. SchulerExecutive Officer, Director
- Rangachari NarasimhanExecutive Officer, Director
- John S. PattonExecutive Officer, Director
- Offering amount
- $12.9M
- Amount sold
- $567K
- First sale
- Sep 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Cardurion6 shared keywordsCardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
AltaThera Pharmaceuticals6 shared keywordsAltaThera Pharmaceuticals develops hospital-use intravenous drug therapies for treating cardiovascular conditions such as atrial fibrillation, atrial flutter, and ventricular arrhythmias in adult and pediatric patients. Its intravenous approach to antiarrhythmic initiation aims to enable faster therapeutic assessment and more precise dosing for physicians in hospital settings.
Companies competing with InCarda Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does InCarda Therapeutics do?
- Incardatherapeutics develops drug therapies for treating atrial fibrillation using synergistic combinations of anti-arrhythmic agents, with delivery platforms designed for both hospital and at-home settings. The company targets reducing the clinical and economic burden of atrial fibrillation in the U.S. healthcare system.
- Who are InCarda Therapeutics's investors?
- InCarda Therapeutics's investors include Asset Management Company, HealthCap, Sofinnova Ventures, Deerfield Management Company.
- How much funding has InCarda Therapeutics raised?
- InCarda Therapeutics has disclosed $66M raised across 4 rounds.
- Where is InCarda Therapeutics headquartered?
- InCarda Therapeutics is headquartered in Brisbane, US.